Equillium, Inc. 0FY.F Stock
Equillium, Inc. Price Chart
Equillium, Inc. 0FY.F Financial and Trading Overview
| Equillium, Inc. stock price | 1.35 EUR |
| Previous Close | 0.64 EUR |
| Open | 0.65 EUR |
| Bid | 0.65 EUR x 0 |
| Ask | 0.68 EUR x 0 |
| Day's Range | 0.65 - 0.65 EUR |
| 52 Week Range | 0.41 - 3.04 EUR |
| Volume | 1K EUR |
| Avg. Volume | 17 EUR |
| Market Cap | 22.3M EUR |
| Beta (5Y Monthly) | 1.19494 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14 EUR |
0FY.F Valuation Measures
| Enterprise Value | -31461016 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.43783784 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.9051196 |
| Price/Book (mrq) | 0.76235294 |
| Enterprise Value/Revenue | -1.277 |
| Enterprise Value/EBITDA | 1.095 |
Trading Information
Equillium, Inc. Stock Price History
| Beta (5Y Monthly) | 1.19494 |
| 52-Week Change | -64.51% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.04 EUR |
| 52 Week Low | 0.41 EUR |
| 50-Day Moving Average | 0.59 EUR |
| 200-Day Moving Average | 1.22 EUR |
0FY.F Share Statistics
| Avg. Volume (3 month) | 17 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 34.41M |
| Float | 18.82M |
| Short Ratio | N/A |
| % Held by Insiders | 31.88% |
| % Held by Institutions | 30.30% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -117.50% |
| Operating Margin (ttm) | -117.11% |
| Gross Margin | 100.00% |
| EBITDA Margin | -116.61% |
Management Effectiveness
| Return on Assets (ttm) | -24.70% |
| Return on Equity (ttm) | -70.69% |
Income Statement
| Revenue (ttm) | 24.64M EUR |
| Revenue Per Share (ttm) | 0.72 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 15.76M EUR |
| EBITDA | -28731000 EUR |
| Net Income Avi to Common (ttm) | -28951000 EUR |
| Diluted EPS (ttm) | -0.85 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 61.99M EUR |
| Total Cash Per Share (mrq) | 1.8 EUR |
| Total Debt (mrq) | 8.68M EUR |
| Total Debt/Equity (mrq) | 29.65 EUR |
| Current Ratio (mrq) | 2.193 |
| Book Value Per Share (mrq) | 0.85 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4594000 EUR |
| Levered Free Cash Flow (ttm) | -2744125 EUR |
Profile of Equillium, Inc.
| Country | Germany |
| State | CA |
| City | La Jolla |
| Address | 2223 Avenida De La Playa |
| ZIP | 92037 |
| Phone | 858 412 5302 |
| Website | https://equilliumbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 37 |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Q&A For Equillium, Inc. Stock
What is a current 0FY.F stock price?
Equillium, Inc. 0FY.F stock price today per share is 1.35 EUR.
How to purchase Equillium, Inc. stock?
You can buy 0FY.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Equillium, Inc.?
The stock symbol or ticker of Equillium, Inc. is 0FY.F.
Which industry does the Equillium, Inc. company belong to?
The Equillium, Inc. industry is Biotechnology.
How many shares does Equillium, Inc. have in circulation?
The max supply of Equillium, Inc. shares is 36.92M.
What is Equillium, Inc. Price to Earnings Ratio (PE Ratio)?
Equillium, Inc. PE Ratio is now.
What was Equillium, Inc. earnings per share over the trailing 12 months (TTM)?
Equillium, Inc. EPS is -0.32 EUR over the trailing 12 months.
Which sector does the Equillium, Inc. company belong to?
The Equillium, Inc. sector is Healthcare.